Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
LTRN

LTRN - Lantern Pharma Inc Stock Price, Fair Value and News

$2.44-0.09 (-3.56%)
Market Closed

20/100

LTRN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

20/100

LTRN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

LTRN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LTRN Price Action

Last 7 days

-9.6%

Last 30 days

-14.4%

Last 90 days

-32.2%

Trailing 12 Months

-34.8%

LTRN RSI Chart

LTRN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LTRN Valuation

Market Cap

27.3M

Price/Earnings (Trailing)

-1.44

Price/Sales (Trailing)

49.01

Price/Free Cashflow

-1.62

LTRN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

LTRN Fundamentals

LTRN Revenue

Revenue (TTM)

556.8K

Rev. Growth (Yr)

-47.26%

Rev. Growth (Qtr)

-12.05%

LTRN Earnings

Earnings (TTM)

-18.9M

Earnings Growth (Yr)

7.29%

Earnings Growth (Qtr)

3.55%

LTRN Profitability

Return on Equity

-197.36%

Return on Assets

-138.85%

Free Cashflow Yield

-61.79%

LTRN Investor Care

Shares Dilution (1Y)

3.71%

Diluted EPS (TTM)

-1.75

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025730.8K644.5K556.8K0
2024756.7K748.1K739.4K0
2023315.7K378.5K0765.4K
2022102.0K136.1K170.2K204.4K
202100067.9K
Get all data in R, Python etc through our Historical Stock Data APIs

About Lantern Pharma Inc

LTRN
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma. In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
 CEO
 WEBSITElanternpharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES22

Lantern Pharma Inc Frequently Asked Questions

LTRN is the stock ticker symbol of Lantern Pharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Lantern Pharma Inc is 27.29 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, LTRN's PE ratio (Price to Earnings) is -1.44 and Price to Sales (PS) ratio is 49.01. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LTRN PE ratio will change depending on the future growth rate expectations of investors.